ATXN3 and Alzheimer disease: Collectively, the AAV-CYP46A1 delivery to animal models of AD, HD, Sca3, and ALS enabled major insights into the role of the CYP46A1 defect in neurodegenerative diseases and CYP46A1 mechanisms of therapeutic action.